Elisabetta Bonzano MD, PhD· @to_be_elizabeth · X·· 1 day agoScore70
Body · original
📌 Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib + fulvestrant in pts with HR+/HER2- advanced/mBC who progressed on prior CDK4/6i in a randomized phase 2 study (FOURLIGHT-1)
✨ @antgiorda
#ESMO26 🇪🇸 @OncoAlert #OncoAlertAF
136 views · 6 likes · 5 reposts · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgSource: Elisabetta Bonzano MD, PhD · x.com